Amylin's board of directors now includes Icahn, Eastbourne nominees

By Lisa Kerner

Charlotte, N.C., June 10 - Amylin Pharmaceuticals, Inc. said its independent inspector of elections issued a final report for the company's May 27 annual meeting of stockholders.

Stockholders voted to elect to Amylin's board of directors Adrian Adams, Steven R. Altman, Daniel M. Bradbury, Teresa Beck, Paul N. Clark, Paulo F. Costa, Karin Eastham, Dr. James R. Gavin, Dr. Jay S. Skyler, Joseph P. Sullivan and shareholder nominees Dr. Alexander J. Denner and Dr. M. Kathleen Behrens, according to a form 8-K filed with the Securities and Exchange Commission on Tuesday.

Denner was nominated by Carl Icahn, and Behrens was nominated by Eastbourne Capital Management, LLC.

Also at the meeting, stockholders voted to approve Amylin's 2009 equity incentive plan and an amendment to Amylin's 2001 employee stock purchase plan increasing the total number of shares authorized for issuance under the plan to 1.5 million.

Amylin is a San Diego biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.